NEW YORK (Thomson Financial) - St. Jude Medical Inc. Tuesday said it has
received approval from the Food and Drug Administration for its Merlin home
transmitter, a radio-frequency wireless technology that remotely monitors
patients' implanted cardiac devices.
The Merlin will be available in the U.S. early this fall and internationally
in the fourth quarter, the company said.
St. Jude shares closed at $42.92 on Monday.
Christie Rizk
cr/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|